3 Million Canadians Use GLP-1 Drugs as Generic Competition Looms

A new survey has revealed that approximately 3 million Canadian adults are currently using GLP-1 medications such as Ozempic and Mounjaro, representing significant market penetration as the country prepares for generic competition later this year.

Survey Highlights Widespread Adoption

The poll conducted by Leger Healthcare found that more than half of survey respondents taking GLP-1 medications reported decreased appetite, while 40 percent experienced fewer food cravings. The survey suggests these effects are reshaping consumer behavior across Canada.

Current users are taking various medications in the GLP-1 class, including Ozempic and Mounjaro, which require prescriptions from healthcare providers.

Cost Remains Primary Barrier

Despite the substantial user base, the survey indicated that many more Canadians would like to access these medications but are prevented by cost considerations. Current retail pricing can reach between $400-$570 CAD monthly for medications like Wegovy, making affordability a significant concern for potential users.

The cost barrier may be addressed as Health Canada continues reviewing nine generic semaglutide applications, with industry experts expecting approvals in the third quarter of 2026. Generic competition typically reduces medication costs by 50-80% compared to brand-name versions.

Market Dynamics Shifting

The 3 million user figure represents substantial market penetration in Canada's adult population of approximately 30 million. This usage level occurs while the semaglutide patent has already expired in Canada as of January 4, 2026, opening the door for generic manufacturers.

Several pharmaceutical companies have positioned themselves for the Canadian generic market, including Sandoz, which has described Canada as the world's second-largest semaglutide market. The regulatory pathway for generics became available after Novo Nordisk's data exclusivity period ended.

Insurance Coverage Patterns

The survey data suggests that improved insurance coverage and low-cost generic options could encourage additional Canadians to access GLP-1 therapies. Currently, coverage varies significantly across private insurance plans and provincial drug programs.

Canadians seeking information about current coverage options can utilize resources such as the insurance coverage checker to understand their potential out-of-pocket costs under different scenarios.

Regulatory Timeline

Health Canada has not provided specific timelines for generic approvals, citing its broader review backlog. However, the regulator is actively processing the nine submitted applications for generic semaglutide products.

Individuals interested in tracking generic availability can monitor the generic semaglutide tracker for updates on regulatory decisions and market entry dates. Additional information about GLP-1 medications is available through the comprehensive FAQ section.

Provincial Variations

The survey data encompasses users across all Canadian provinces, though specific provincial breakdowns were not detailed in the available information. Access patterns may vary by region based on provincial drug coverage policies and pharmacy distribution networks.

Major pharmacy chains including Shoppers Drug Mart, Costco, and Walmart currently stock these medications where available, with pricing potentially varying by location and supplier agreements.

This article is for informational purposes only and does not constitute medical advice.